Podcast Pearls
Role of TKIs in Nonadipocytic Soft Tissue Sarcoma and Advanced Osteosarcoma

Download this summary slideset to accompany a podcast featuring expert discussion on key clinical trial data on leveraging TKIs as single agents or in combination with cytotoxics or immune checkpoint inhibitors for treatment of soft tissue sarcomas and osteosarcoma.
person default
Jean Yves Blay, MD, PhD
Robin L. Jones, BSc, MBBS, MRCP, MD(Res)
Format: Microsoft PowerPoint (.ppt)
File Size: 393 KB
Released: November 3, 2021

Acknowledgements

Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.

Related Content

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered malignancies.

Alexander Drilon, MD
Program Director
Thomas Stinchcombe, MD
Program Director
Released: August 4, 2022

Gain expert insight on managing NTRK- and RET-altered malignancies and optimal methods for detecting gene fusions, in this webcast from Clinical Care Options (CCO)

Alexander Drilon, MD
Program Director
Thomas Stinchcombe, MD
Program Director
person default Saad A. Khan, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 10, 2022 Expired: June 9, 2023

Dr. Robin L. Jones offers expert commentary on TKI therapy in advanced osteosarcoma and nonadipocytic sarcoma, from Clinical Care Options (CCO)

Robin L. Jones, BSc, MBBS, MRCP, MD(Res) Released: May 25, 2022

Clinical Care Options (CCO): Joshua Sabari, MD, provides insights into the emerging targeted therapies for patients with NRG1-positive solid tumors

Joshua Sabari, MD Released: February 28, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings